[go: up one dir, main page]

DK0382271T3 - Tocoler as adjuvants in vaccines - Google Patents

Tocoler as adjuvants in vaccines

Info

Publication number
DK0382271T3
DK0382271T3 DK90200127.0T DK90200127T DK0382271T3 DK 0382271 T3 DK0382271 T3 DK 0382271T3 DK 90200127 T DK90200127 T DK 90200127T DK 0382271 T3 DK0382271 T3 DK 0382271T3
Authority
DK
Denmark
Prior art keywords
vaccines
tocoler
adjuvants
tocols
adjuvant
Prior art date
Application number
DK90200127.0T
Other languages
Danish (da)
Inventor
Lammert Cornelius
Eric Onno Rijke
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0382271T3 publication Critical patent/DK0382271T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oil based vaccines often cause serious local side effects at the site of administration and/or have a high viscosity which make said vaccines difficult to handle. Vaccines comprising as an adjuvant a stable emulsion of tocols in water do not display these undesired effects and induce good immune responses.
DK90200127.0T 1989-02-04 1990-01-18 Tocoler as adjuvants in vaccines DK0382271T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8900277 1989-02-04

Publications (1)

Publication Number Publication Date
DK0382271T3 true DK0382271T3 (en) 1995-05-01

Family

ID=19854075

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90200127.0T DK0382271T3 (en) 1989-02-04 1990-01-18 Tocoler as adjuvants in vaccines

Country Status (15)

Country Link
US (2) US5650155A (en)
EP (1) EP0382271B1 (en)
JP (1) JP2892739B2 (en)
KR (1) KR0162646B1 (en)
CN (1) CN1056085C (en)
AT (1) ATE115862T1 (en)
AU (1) AU633043B2 (en)
CA (1) CA2008856C (en)
DE (1) DE69015222T2 (en)
DK (1) DK0382271T3 (en)
ES (1) ES2068989T3 (en)
GR (1) GR3015438T3 (en)
HU (1) HU206989B (en)
NZ (1) NZ232354A (en)
ZA (1) ZA90512B (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (en) 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
ATE403436T1 (en) * 1999-03-24 2008-08-15 Secr Defence POLYCATIONIC CARBOHYDRATES AS IMMUNOSTIMULANT AGENTS IN VACCINES
DK2266603T3 (en) 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa tumor Vaccines
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
TW200700079A (en) 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Composition
AU2006289102C1 (en) * 2005-09-09 2017-11-30 Intervet International B.V. PCV-2 vaccine
DK179025B1 (en) 2005-09-16 2017-08-28 Intervet Int Bv fish vaccine
CN103251940A (en) 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 Vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1998802A2 (en) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
MX2009000660A (en) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Influenza vaccine.
EP2491947A3 (en) 2006-09-07 2012-10-17 GlaxoSmithKline Biologicals S.A. Vaccine
HUE036180T2 (en) 2006-09-26 2018-06-28 Infectious Disease Res Inst Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2433648A3 (en) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
PT2086582E (en) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vaccine comprising an oil in water emulsion adjuvant
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
MX2009013949A (en) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates.
ATE547118T1 (en) 2007-08-28 2012-03-15 Univ Liege RECOMBINANT KOI HERPES VIRUS (KHV) OR CYPRINID HERPES VIRUS 3 (CYHV-3) AND VACCINE FOR PREVENTING DISEASE CAUSED BY KHV/CYHV-3 IN CYPRINUS CARPIO CARPIO OR CYPRINUS CARPIO KOI
US7741418B2 (en) * 2007-12-31 2010-06-22 Bridgestone Corporation Process for producing polydienes
MX2010011412A (en) 2008-04-16 2010-11-12 Glaxosmithkline Biolog Sa Vaccine.
TWI551295B (en) 2008-04-18 2016-10-01 英特威特國際股份有限公司 Vaccine for protection against lawsonia intracellularis
TWI449533B (en) 2008-04-18 2014-08-21 Intervet Int Bv Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus
RU2523561C2 (en) * 2008-04-18 2014-07-20 Интервет Интернэшнл Б.В. Vaccine against lawsonia intracellularis
AR071220A1 (en) 2008-04-28 2010-06-02 Intervet Int Bv ASTROVIRUS AVIARIO DEPOSITED UNDER THE NUERO CNCM I-3895
EP2328614A1 (en) * 2008-08-06 2011-06-08 Novartis AG Microparticles for use in immunogenic compositions
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
EP2393922A1 (en) 2009-02-06 2011-12-14 GlaxoSmithKline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US9341623B2 (en) 2009-09-25 2016-05-17 Glaxosmithkline Biologicals Sa Immunodiffusion assay for influenza virus
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
SG183514A1 (en) 2010-03-11 2012-10-30 Immune Design Corp Vaccines for pandemic influenza
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
SG189176A1 (en) 2010-10-15 2013-05-31 Glaxosmithkline Biolog Sa Cytomegalovirus gb antigen
EP2629794B1 (en) 2010-10-18 2017-06-07 Intervet International B.V. Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
CA2819297A1 (en) 2010-12-14 2012-06-21 Glaxosmithkline Biologicals S.A. Mycobacterium antigenic composition
WO2012089748A1 (en) 2010-12-29 2012-07-05 Intervet International B.V. Canine babesiosis vaccine antigen
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
AR087811A1 (en) 2011-09-08 2014-04-16 Umc Utrecht Holding Bv VACCINE AGAINST STAPHYLOCOCCUS AUREUS
UA114719C2 (en) 2011-12-30 2017-07-25 Гесваль С.А. A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
WO2013113865A1 (en) 2012-02-03 2013-08-08 The Pirbright Institute Eimeria vector vaccine for campylobacter jejuni
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccine against HSV-2
ES2939307T3 (en) 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa immunogenic composition
AU2014243149B2 (en) 2013-03-26 2017-11-23 The Pirbright Institute Stabilised FMDV capsids
BR112015024882B8 (en) 2013-03-29 2024-02-27 Intervet Int Bv Composition, vaccine against rhipicephalus ticks, methods for preparing a composition and a vaccine against rhipicephalus ticks, use of bm86 protein and a subolesin protein, and, kit of parts
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
CN110438090B (en) 2013-05-31 2023-12-05 英特维特国际股份有限公司 Scale desquamation disease (SDD) causative virus and its derivatives
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015028546A1 (en) 2013-08-30 2015-03-05 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
CN104436157A (en) 2013-09-23 2015-03-25 恩金生物有限公司 Influenza vaccine and therapy
CR20160369A (en) 2014-01-21 2016-10-05 Immune Desing Corp COMPOSITIONS FOR USE IN THE TREATMENT OF ALLERGIC AFFECTIONS
CN104013955B (en) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 A kind of not containing O/w emulsion and uses thereof of surfactant
WO2015197737A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition
AR102548A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST HAND, FEET AND MOUTH DISEASE AND MANUFACTURING AND USE METHODS
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
US20170369854A1 (en) 2014-12-16 2017-12-28 Glaxosmithkline Biologicals Sa A method for a large scale virus purification
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
CN110087678B (en) * 2016-12-23 2023-09-26 英特维特国际股份有限公司 Combination vaccines for pigs
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
US11141377B2 (en) 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
CA3081581A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
EP3720488A1 (en) * 2017-12-04 2020-10-14 Intervet International B.V. Vaccination with replicon particles and oil adjuvant
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
EP3662929A1 (en) 2018-12-07 2020-06-10 IDT Biologika GmbH A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv
AU2020318680B2 (en) 2019-07-21 2025-04-24 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
KR102617710B1 (en) 2020-08-05 2024-01-25 주식회사 이노헨스 Substrate treatment apparatus
CA3202549A1 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
US20250281597A1 (en) 2021-10-25 2025-09-11 Intervet Inc. A vaccine for the protection of piglets against swine influenza a virus infection
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US20250161421A1 (en) 2022-02-03 2025-05-22 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
CN114984201B (en) * 2022-04-24 2025-10-17 国药中生生物技术研究院有限公司 Natural lipid drop-like nanoemulsion adjuvant and preparation method thereof
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025032535A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025262124A1 (en) 2024-06-19 2025-12-26 Intervet International B.V. Adjuvanted veterinary vaccines against enteric diseases
WO2025262123A1 (en) 2024-06-19 2025-12-26 Intervet International B.V. Veterinary vaccines against enteric diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
NL8301996A (en) * 1983-06-06 1985-01-02 Duphar Int Res METHOD FOR PREPARING ADVISED LIVE VACCINES AND SO OBTAINED VACCINES OBTAINED.
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
AU596581B2 (en) * 1986-04-15 1990-05-10 Sansho Seiyaku Co., Ltd. Topical agents for inhibiting the melanin generation
ZA872532B (en) * 1986-04-21 1987-11-25 Akzo Nv Combined vaccine
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines

Also Published As

Publication number Publication date
KR900012630A (en) 1990-09-01
CN1056085C (en) 2000-09-06
HUT56285A (en) 1991-08-28
EP0382271B1 (en) 1994-12-21
EP0382271A1 (en) 1990-08-16
DE69015222D1 (en) 1995-02-02
AU633043B2 (en) 1993-01-21
CA2008856C (en) 2001-06-19
KR0162646B1 (en) 1998-12-01
ATE115862T1 (en) 1995-01-15
ZA90512B (en) 1990-11-28
DE69015222T2 (en) 1995-05-04
US5667784A (en) 1997-09-16
NZ232354A (en) 1991-09-25
JP2892739B2 (en) 1999-05-17
HU206989B (en) 1993-03-01
US5650155A (en) 1997-07-22
CN1044594A (en) 1990-08-15
GR3015438T3 (en) 1995-06-30
HU900653D0 (en) 1990-04-28
CA2008856A1 (en) 1990-08-04
ES2068989T3 (en) 1995-05-01
JPH02250835A (en) 1990-10-08
AU4897590A (en) 1990-08-09

Similar Documents

Publication Publication Date Title
DK0382271T3 (en) Tocoler as adjuvants in vaccines
LU91485I2 (en) An influenza adjuvant vaccine in which the adjuvant is an oil-in-water emulsion comprising squalene, DL-a-tocopherol and polysorbate 80
ATE199644T1 (en) A HYDROPHOBIC SULFOLIPIDIC POLYSACCHARIDE ADJUVANT FOR VACCINES
ES2179105T3 (en) PROTEIN ASSISTANTS.
FI925835A0 (en) VACCINER INNEHAOLLANDE LIPOSOMER
ES2034188T3 (en) COSMETIC COMPOSITIONS.
ATE149091T1 (en) VACCINE ADJUVANT CONTAINING A TETRA-POLYOL
KR870012641U (en) Telescopic adjustable glasses legs